Lilly cuts Germany investment plan in half over healthcare reforms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
June 5, 2026 7:38 AM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,344.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Mounjaro TRx/NRx scripts for the week ending 5/29/26 were ~756,700/353,700 (vs. ~796,800/388,900 last week) per IQVIA data. Zepbound TRx/NRx scripts were ~610,800/328,300 (vs. ~659,000/360,200 last week). We see ~7% upside to '26 M+Z ests. We are monitoring the launches of LLY's Mounjaro (injectable GLP-GIP) for type 2 diabetes (T2D), and Zepbound (injectable GLP-GIP) for obesity, and Foundayo (oral GLP) given these are the company's key product cycles. Total GLP-1 TRx (LLY+Novo) grew ~32% yoy (see... More
